Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAUTAM BORTHAKUR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1629177944
CMS profile
346312
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,357.33

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,280.00 2
Food and Beverage $77.33 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $2,679.99 2
Takeda Pharmaceuticals U.S.A., Inc. $677.34 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAUTAM BORTHAKUR

NPI 1629177944 · CMS profile ID 346312

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $3,357.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $2,620.0012/06/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658935717 CMS
Novartis Pharmaceuticals Corporation $59.9912/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658935723 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.3409/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697401041 CMS
Takeda Pharmaceuticals U.S.A., Inc. $660.0006/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697373893 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,357.33 4
PY2021 $272.24 2
PY2022 $3,052.27 7
PY2023 $3,419.07 6
PY2024 $112.20 2
PY2025 $151.62 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $481,974.58 1
PY2024 Principal investigator $79,669.55 3
PY2023 Recipient $71,592.50 1
PY2023 Principal investigator $36,848.00 3
PY2022 Principal investigator $569,901.54 33
PY2021 Principal investigator $404,764.38 36
PY2020 Recipient $1,087.58 1
PY2020 Principal investigator $558,754.27 55
PY2019 Recipient $103.92 2
PY2019 Principal investigator $1,118,089.03 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $2,065.00 12/18/2019 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, No dispute reported 06/30/2026 709081531
Recipient GlaxoSmithKline, LLC. $53.35 12/08/2019 Covered Recipient Physician A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF No dispute reported 06/30/2026 709080923
Recipient GlaxoSmithKline, LLC. $50.57 12/08/2019 Covered Recipient Physician A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF No dispute reported 06/30/2026 709082277
Principal investigator 1 Incyte Corporation $95.00 12/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666473047
Principal investigator 1 Incyte Corporation $95.00 11/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666473043
Principal investigator 1 GlaxoSmithKline, LLC. $1,971.00 10/30/2019 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, No dispute reported 06/30/2026 669973091
Principal investigator 1 GlaxoSmithKline, LLC. $190,524.34 10/09/2019 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 669961651
Principal investigator 1 Incyte Corporation $95.00 10/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666473039
Principal investigator 1 GlaxoSmithKline, LLC. $9,316.50 09/10/2019 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS
A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, No dispute reported 06/30/2026 669975435
Principal investigator 1 Incyte Corporation $111.90 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507729
Principal investigator 1 Incyte Corporation $95.50 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507731
Principal investigator 1 Incyte Corporation $109.80 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507733
Principal investigator 1 Incyte Corporation $754.32 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507735
Principal investigator 1 Incyte Corporation $65.60 09/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507737
Principal investigator 1 Incyte Corporation $95.00 09/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472857
Principal investigator 1 Janssen Research & Development, LLC $14,248.60 08/22/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open-Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 654240989
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,061.70 08/13/2019 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
To assess safety and tolerability describe the dose limiting toxicities determine the maximum tolerated dose MTD or the highest protocol defined dose maximum administered dose in the absence of establishing the MTD and a recommended dose for further evaluation of MEDI7247 in patients with selected hematological malignancies who have relapsed after or are refractory to prior standard therapy and for whom there is no standard salvage regimen available No dispute reported 06/30/2026 685004341
Principal investigator 1 Incyte Corporation $43.92 08/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507725
Principal investigator 1 Incyte Corporation $38.20 08/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507727
Principal investigator 1 Incyte Corporation $95.00 08/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472853
Principal investigator 1 Incyte Corporation $4.20 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507707
Principal investigator 1 Incyte Corporation $1.16 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507709
Principal investigator 1 Incyte Corporation $28.65 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507711
Principal investigator 1 Incyte Corporation $2.76 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507713
Principal investigator 1 Incyte Corporation $70.50 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507715
Principal investigator 1 Incyte Corporation $85.50 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507717
Principal investigator 1 Incyte Corporation $7.40 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507719
Principal investigator 1 Incyte Corporation $3.06 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507721
Principal investigator 1 Incyte Corporation $65.88 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507723
Principal investigator 1 Incyte Corporation $28.65 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507739
Principal investigator 1 Incyte Corporation $28.65 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507741
Principal investigator 1 Incyte Corporation $28.65 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507743
Principal investigator 1 Incyte Corporation $70.50 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507745
Principal investigator 1 Incyte Corporation $70.50 07/10/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507747
Principal investigator 1 Incyte Corporation $95.00 07/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472849
Principal investigator 1 GlaxoSmithKline, LLC. $7,002.00 06/21/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS FOUNDATION
A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, No dispute reported 06/30/2026 669961259
Principal investigator 1 Novartis Pharmaceuticals Corporation $577,845.87 06/18/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
ELTROMBOPAG FOR THE MANAGEMENT OF THROMBOCYTOPENIA ASSOCIATED WITH TYROSINE KINASE THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CML No dispute reported 06/30/2026 640729973
Principal investigator 1 Incyte Corporation $1,825.43 06/11/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666458787
Principal investigator 1 GlaxoSmithKline, LLC. $25,325.00 06/04/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS FOUNDATION
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 669961027
Principal investigator 1 Incyte Corporation $95.00 06/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472845
Principal investigator 1 Eli Lilly and Company $54,615.00 05/06/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PH I/IB - CHK-1 INHIB II + FLUDARABINE + CYTARABINE - AML No dispute reported 06/30/2026 654287141
Principal investigator 1 Incyte Corporation $95.00 05/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472839
Principal investigator 1 Janssen Research & Development, LLC $14,248.60 04/29/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open-Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 654240991
Principal investigator 1 GlaxoSmithKline, LLC. $20,074.10 04/16/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS
A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, No dispute reported 06/30/2026 669963281
Principal investigator 1 GlaxoSmithKline, LLC. $57,500.00 04/04/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 3
A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF No dispute reported 06/30/2026 669973897
Principal investigator 1 Incyte Corporation $95.00 04/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472833
Principal investigator 1 Incyte Corporation $377.16 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507601
Principal investigator 1 Incyte Corporation $70.50 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507603
Principal investigator 1 Incyte Corporation $28.65 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507605
Principal investigator 1 Incyte Corporation $32.94 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507607
Principal investigator 1 Incyte Corporation $60.15 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507609
Principal investigator 1 Incyte Corporation $47.75 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507611
Principal investigator 1 Incyte Corporation $104.50 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507613
Principal investigator 1 Incyte Corporation $14.80 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507615
Principal investigator 1 Incyte Corporation $3.74 03/08/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666507617
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 03/07/2019 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 3
A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, No dispute reported 06/30/2026 669956769
Principal investigator 1 Incyte Corporation $95.00 03/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472657
Principal investigator 1 Incyte Corporation $8,280.70 02/07/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666458695
Principal investigator 1 Incyte Corporation $95.00 02/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472651
Principal investigator 1 Janssen Research & Development, LLC $14,248.60 01/17/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
An Open-Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 654241001
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $51,841.10 01/04/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
Maximum Tolerated Dose Study Japan Global expansion No dispute reported 06/30/2026 639761803
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB059872 as Monotherapy and Combination Therapy in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666472645